The same clone is also sold as:
- Bio-Rad: MCA2265, MCA2265GA
- Antibodies-online: ABIN1106226
- Santa Cruz Biotechnology: sc-47723
- LifeSpan Biosciences: LS-C179741, LS-C140021, LS-C202191, LS-C10786, LS-C202190, LS-C140022, LS-C44521, LS-C140020, LS-C139879, LS-C202164, LS-C139877, LS-C139878, LS-C202165
Reference |
---|
Selleri S, Arnaboldi F, Palazzo M, Gariboldi S, Zanobbio L, Opizzi E, et al. Toll-like receptor agonists regulate beta-defensin 2 release in hair follicle. Br J Dermatol. 2007;156:1172-7 pubmed
|
Chen L, Arora M, Yarlagadda M, Oriss T, Krishnamoorthy N, Ray A, et al. Distinct responses of lung and spleen dendritic cells to the TLR9 agonist CpG oligodeoxynucleotide. J Immunol. 2006;177:2373-83 pubmed
|
Methe H, Kim J, Kofler S, Weis M, Nabauer M, Koglin J. Expansion of circulating Toll-like receptor 4-positive monocytes in patients with acute coronary syndrome. Circulation. 2005;111:2654-61 pubmed
|
Azulay-Debby H, Edry E, Melamed D. CpG DNA stimulates autoreactive immature B cells in the bone marrow. Eur J Immunol. 2007;37:1463-75 pubmed
|
Tsujimoto H, Ono S, Matsumoto A, Kawabata T, Kinoshita M, Majima T, et al. A critical role of CpG motifs in a murine peritonitis model by their binding to highly expressed toll-like receptor-9 on liver NKT cells. J Hepatol. 2006;45:836-43 pubmed
|
Tokumasa N, Suto A, Kagami S, Furuta S, Hirose K, Watanabe N, et al. Expression of Tyk2 in dendritic cells is required for IL-12, IL-23, and IFN-gamma production and the induction of Th1 cell differentiation. Blood. 2007;110:553-60 pubmed
|
Xu W, He B, Chiu A, Chadburn A, Shan M, Buldys M, et al. Epithelial cells trigger frontline immunoglobulin class switching through a pathway regulated by the inhibitor SLPI. Nat Immunol. 2007;8:294-303 pubmed
|
Pompei L, Jang S, Zamlynny B, Ravikumar S, McBride A, Hickman S, et al. Disparity in IL-12 release in dendritic cells and macrophages in response to Mycobacterium tuberculosis is due to use of distinct TLRs. J Immunol. 2007;178:5192-9 pubmed
|
Abe M, Thomson A. Dexamethasone preferentially suppresses plasmacytoid dendritic cell differentiation and enhances their apoptotic death. Clin Immunol. 2006;118:300-6 pubmed
|
5405 PB UDEN
Hycult Biotech’s mission and strategy is to advance insight in innate immunity related diseases, for the benefit of individuals and their quality of life.
As a leader within focused fields of immunology and cell biology, we develop products for the life sciences and in accordance with our mission it is our ambition to facilitate the transition of these products from research use into diagnostic testing. Many of our reagents are developed in close cooperation with scientists worldwide. Hycult Biotech has built a strong network with over 40 close scientific collaborations with leading international research institutes. We contribute to numerous projects and as a result, can continuously offer early access to an expanding range of innovative reagents. Hycult Biotech has been ISO-9001 certified since 1998 and we upgraded our certification to ISO-13485 in 2007, with a milestone of our first release of CE marked assays in 2009. Our vision, knowledgeable team and quality management system guarantee products of the highest grade combined with excellent technical service.